DUBLIN--(BUSINESS WIRE)--The "Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering.
Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, with symptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities. There are a total of 61 products in development for this indication, by 40 companies and five academic institutions. Key companies operating in this pipeline space include NLS Pharma Group and Shire.
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. There are a total of 191 products in development for this indication, by 112 companies and 20 academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, Sumitomo Dainippon Pharma, Luye Pharma Group, Otsuka Holdings and Vanderbilt University.
Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. There are a total of 134 products in development for this indication, by 85 companies and nine academic institutions. Key companies operating in this pipeline space include Omeros Corp, Suven Life Sciences, Heptares Therapeutics, Merck & Co, Sumitomo Dainippon Pharma and Vanderbilt University.
Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. There are a total of 11 products in development for this indication, by nine companies and one academic institution. Key companies operating in this pipeline space include Catalyst Pharmaceuticals, who are fielding two pipeline products.
Across all four of these indications, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.
- Alcobra Ltd
- Alkermes Plc
- Allergan Plc
- Alvogen Korea Co Ltd
- Amarantus Bioscience Holdings Inc
- Amorsa Therapeutics Inc
- Anavex Life Sciences Corp
- Angelini Group
- Angita BV
- Araim Pharmaceuticals Inc
- Arbor Pharmaceuticals LLC
- Eli Lilly and Company
- Ensysce Biosciences Inc
- Evotec AG
- F. Hoffmann-La Roche Ltd
- FPRT Bio Inc
- Fabre-Kramer Pharmaceuticals Inc
- Intas Pharmaceuticals Ltd
- Integrative Research Laboratories Sweden AB
- Intra-Cellular Therapies Inc
- Johnson & Johnson
- KemPharm Inc
- Lead Discovery Center GmbH
- Les Laboratoires Servier SAS
- Mitsubishi Tanabe Pharma Corp
Key Topics Covered:
1. Research Report Guidance
2. Executive Summary
3. Neuropsychiatric Disorder Cluster Report Coverage
4. Therapeutics Development
5. Therapeutics Assessment
6. Companies Involved in Therapeutics Development
7. Dormant Projects
8. Discontinued Products
9. Product Development Milestones
For more information about this report visit https://www.researchandmarkets.com/research/j5qvbs/neuropsychiatric